Enliven Therapeutics, Inc.

Listed Company

ELVNCIK 0001672619NasdaqNon-AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-103.69M

Total Assets

$476.17M

Equity

$459.60M

Shares Out

59.80M

Op. Cash Flow

$-70.30M

Business

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision oncology, chemistry-led approach. It advances lead product candidates ELVN-001, a selective BCR-ABL kinase inhibitor for chronic myeloid leukemia, and ELVN-002, a CNS-penetrant, irreversible HER2 inhibitor, along with multiple discovery-stage small molecule programs. Its key business areas include its BCR-ABL and HER2 development programs, target- and indication-agnostic discovery efforts, and clinical development operations. It conducts clinical trials in multiple geographies (including the United States and Japan), holds worldwide development and commercial rights, and relies on third-party contract manufacturing and CRO partnerships for supply and distribution.

Summary from filing dated 2025-03-13

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	86	81	65	31	38
General and administrative	34	24	19	8	13
Total operating expenses	120	105	84	39	51
Loss from operations	−120	−105	−84	−39	−51
Interest income	16	15	12	1	233,000
Change in fair value of contingent value right liability	0	873,000	0	—	—
Income tax expense	0	−232,000	0	88,000	—
Other expense	−49,000	−2,000	−22,000	0	−175,000
Total other income (expense), net	16	16	12	1	58,000
Net loss	−104	−89	−72	−38	−51
Net unrealized gains (losses) on marketable securities	279,000	−86,000	141,000	0	−20,000
Comprehensive loss	−103	−89	−71	−38	−51
Net loss per share, basic	−1.83	−1.89	−2.01	−12.05	−2.37
Net loss per share, diluted	−1.83	−1.89	−2.01	−12.05	−2.37
Weighted-average shares outstanding, basic	57	47	36	3	22
Weighted-average shares outstanding, diluted	57	47	36	3	22

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2025 2025-01-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2023 2023-02-28
Cash and cash equivalents	99	—	124	100	—
Marketable securities	364	—	189	153	—
Restricted cash	0	—	54,000	54,000	—
Prepaid expenses and other current assets	12	—	5	3	—
Total current assets	475	—	318	266	—
Property and equipment, net	34,000	—	458,000	742,000	—
Operating lease right-of-use assets	383,000	700,000	0	320,000	—
Deferred offering costs	217,000	—	0	563,000	—
Other long-term assets	656,000	—	7	4	—
Total assets	476	—	326	272	—
Accounts payable	2	—	1	532,000	—
Accrued expenses and other current liabilities	14	—	15	15	—
Total current liabilities	17	—	16	26	—
Total liabilities	17	—	16	26	—
Commitments and contingencies (Note 8)	—	—	—	—	—
Preferred stock, par value $0.001; authorized shares - 10,000,000; issued and outstanding shares - none	0	—	0	0	—
Common stock, par value $0.001; authorized shares - 100,000,000; issued and outstanding shares - 59,440,045 and 48,936,459 at December 31, 2025 and 2024, respectively	59,000	—	49,000	41,000	165
Additional paid-in capital	806	—	553	400	—
Accumulated other comprehensive income	334,000	—	55,000	141,000	—
Accumulated deficit	−347	—	−243	−154	—
Total stockholders' equity	460	—	310	246	—
Total liabilities and stockholders' equity	476	—	326	272	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	263,000	317,000	297,000	215,000	100,000
Stock-based compensation	34	20	13	3	4
Non-cash lease expense	353,000	320,000	306,000	0	—
Amortization of premiums and discounts on marketable securities, net	−227,000	424,000	−5	0	155,000
Loss on disposal of property and equipment	106,000	11,000	—	—	—
Prepaid expenses, other current and long-term assets	−1	−5	−4	−2	−235,000
Operating lease liabilities	−337,000	−335,000	−310,000	4,000	—
Accounts payable	817,000	810,000	−2	411,000	389,000
Accrued expenses and other liabilities	−496,000	−248,000	8	2	393,000
Net cash used in operating activities	−70	−73	−61	−32	−47
Maturities of marketable securities	273	314	120	0	—
Purchases of marketable securities	−447	−351	−268	0	—
Receipt of contingent value right milestone	0	10	0	—	—
Payment of contingent value right milestone, net of permitted deductions	0	−9	0	—	—
Purchases of property and equipment	−158,000	−44,000	−149,000	−612,000	−12,000
Proceeds from sale of property and equipment	213,000	0	—	—	—
Net cash used in investing activities	−174	−36	−148	−612,000	−2
Proceeds from exercise of stock options	2	4	399,000	591,000	860,000
Proceeds from issuance of common stock under the Employee Stock Purchase Plan	620,000	651,000	0	—	—
Proceeds from issuance of common stock and pre-funded warrants in the Public Offering, net of issuance costs	216	0	—	—	—
Proceeds from issuance of common stock and Pre-Funded Warrants in the Private Placement, net of issuance costs	0	90	0	—	—
Proceeds from issuance of common stock under the Sales Agreement, net of issuance costs	0	39	0	—	—
Payment of deferred offering costs	−217,000	0	—	—	—
Net cash provided by financing activities	219	133	234	−2	49
Net (decrease) increase in cash, cash equivalents and restricted cash	−25	24	25	−34	698,000
Income taxes paid related to the contingent value right milestone	0	232,000	0	—	—
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	736,000	0	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro